111-In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00291447
Recruitment Status : Completed
First Posted : February 14, 2006
Last Update Posted : August 15, 2006
Information provided by:
Ludwig Institute for Cancer Research

Brief Summary:
The purpose of this clinical trial is to describe the toxicity, biodistribution, pharmacokinetics and tumour uptake of a single infusion of ch806 (tagged with a trace amount of radioactive 111-Indium: 111In-ch806) in patients with advanced tumours expressing the 806 antigen.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: ch806 Drug: 111-Indium-ch806 Phase 1

Detailed Description:

This clinical research study explores the activity of the new experimental antibody ch806 in humans for the first time.

Cancers arising from an organ can be cured in some cases with various combinations of surgery, chemotherapy and radiotherapy. However, once some cancers spread to other organs, treatment with commonly used methods is unlikely to cure the cancer and so treatment is then designed to control the growth of the cancer and the problems it is causing. One newer treatment approach involves targeting a marker (antigen) called the epidermal growth factor receptor (EGFR), which is found on the tumour cell’s surface, with a specially constructed monoclonal antibody called “ch806”.

Antibodies are proteins that are found in the blood. Antibodies normally protect us from foreign invaders, such as bacteria or viruses. They help destroy these foreign substances by binding to them and activating white blood cells or blood proteins, resulting in their destruction. Tumour cells also have antigens which can be targeted by antibodies. A receptor expressed in high amounts (over-expressed) on various cancer cells, called the epidermal growth factor (EGFR) has been identified, studied and targeted with a variety of antibodies.

One of these antibodies, mAb806, was originally made from mouse protein. Because mAb806 is a mouse antibody, if it were given to humans the body would see it as a foreign protein and would be likely to react to it with an unwanted immune response. To overcome this, the structure of the original mouse antibody called mAb 806 was changed to appear more “human-like”. And the chimeric antibody (part mouse part human) called ch806 was produced.

The study is open to patients whose tumour is shown to express the 806 antigen by a special test. Further tests are required to determine eligibility for the study. These tests determine general health and include: physical examination; blood samples for routine tests; routine tests to determine the extent of tumour prior to starting treatment with 111 In-ch806 (eg. X-ray, CT scan, etc.)

On study, 111In-ch806 is given by infusion into a vein over one hour. Blood samples to determine the amount of drug in the blood (pharmacokinetics), are taken a number of times on the day of the 111 In-ch806 infusion; about every 2nd day for the first week; then 1 week, 2 weeks and 3 weeks after the infusion. Blood tests are also used to monitor general health and to see if the immune system recognises the infused antibody by making another antibody against it. Such a response is called “anti-ch806 antibody” or “HACA”. Gamma camera scans to see where 111 In-ch806 goes in the body are done right after the first infusion, and 3 more times over the next seven days. The scan takes about one hour each time. Visits for weekly follow up examinations and blood tests until 30 days after the infusion are combined with further gamma camera scans. Tumour is reassessed 30 days after the infusion using the same type of scans as at study entry.

Further treatment with a course of 111In-ch806 is not be available at this time, as this study is to test the safety of a single infusion only.

Study Type : Interventional  (Clinical Trial)
Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Single Dose Escalation Trial of ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
Study Start Date : May 2005
Study Completion Date : May 2006

Primary Outcome Measures :
  1. Toxicity as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE).

Secondary Outcome Measures :
  1. Biodistribution of ch806 based on gamma camera images.
  2. Pharmacokinetics of 111In-ch806 and ch806 protein from gamma counting and ELISA of serum samples.
  3. Tumour uptake of 111In-ch806 based on qualitative assessment of biodistribution images and dosimetry.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with advanced or metastatic tumours which are positive for 806 antigen expression based on CISH or IHC of archived tumour samples.
  • Histologically or cytologically proven malignancy.
  • Measurable disease on CT scan with at least one lesion >/= 2 cm diameter (to allow adequate imaging).
  • Karnofsky performance scale >/= 70.
  • Within the last 2 weeks vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified: Neutrophil count >/= 1.5 x 10^9/L; Platelet count >/= 150 x 10^9/L; Serum bilirubin < 34 micromol/L; Creatinine clearance > 50ml/min
  • Able and willing to give valid written informed consent

Exclusion Criteria:

  • Untreated active metastatic disease to the central nervous system (new or enlarging lesions on CT or MRI), or within 3 months of treatment (i.e. surgery or radiotherapy) for brain metastases. Primary central nervous system tumour (e.g. Glioblastoma Multiforme) is not an exclusion criterion.
  • Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.
  • Chemotherapy, radiation therapy, or immunotherapy within 4 weeks before study entry (6 weeks for nitrosoureas).
  • Clinically significant cardiac disease (New York Heart Association Class III/IV)
  • Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.
  • Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
  • Lack of availability for immunological and clinical follow-up assessments.
  • Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
  • Pregnancy or breastfeeding.
  • Women of childbearing potential: Refusal or inability to use effective means of contraception.
  • Concomitant treatment with systemic corticosteroids except for patients with Glioblastoma. (Topical or inhalational corticosteroids are permitted)
  • Prior administration of monoclonal antibody or antibody fragment, and positive human anti-chimeric antibody (HACA) titre.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00291447

Australia, Victoria
Ludwig Institute Tumor Targeting Program, Austin Health
Heidelberg (Melbourne), Victoria, Australia, 3084
Sponsors and Collaborators
Ludwig Institute for Cancer Research
Principal Investigator: A/Prof Andrew M Scott, MBBS MD DDU Ludwig Institute for Cancer Research Identifier: NCT00291447     History of Changes
Other Study ID Numbers: LUD2004-001
First Posted: February 14, 2006    Key Record Dates
Last Update Posted: August 15, 2006
Last Verified: August 2006